Literature DB >> 33095429

Influenza-associated myositis: a single-centre, 5-year retrospective study.

James Kerr1, Kristine Macartney2,3, Philip N Britton4,5.   

Abstract

We aimed to describe the clinical epidemiology of influenza-associated myositis (IAM) over a 5-year period. We identified ICD-10-coded myositis cases retrospectively 2011-2015 and performed limited chart reviews. We excluded myositis with non-viral causes and cross-referenced with laboratory records of influenza tests to identify confirmed IAM. We defined probable IAM as viral myositis occurring during the influenza season without alternative cause. We described epidemiological and clinical features of IAM and compared IAM with all hospitalised influenza. We identified 283 cases of viral myositis with seasonal peaks (May to October, 85% of cases); 69 were tested for influenza, 52 (78%) were positive. Given the strong seasonality concurrent with the influenza season, we estimated that 80% (95% CI 76-85) of viral myositis is attributable to IAM annually. Of 226 cases of IAM, 21% (n = 49) were confirmed and the remaining probable. IAM was associated with being male (82%), aged 5-9 (73%), and influenza B (86%). The majority had bilateral calf pain; mean creatinine kinase (CK) value was 3579 U/L, and no cases had renal impairment.
Conclusion: Childhood viral myositis shows strong association with the influenza season. IAM is clinically stereotyped, age restricted, and benign in most and strongly associated with influenza B. What is Known: • Childhood viral myositis has been reported in association with influenza for decades, more frequently with influenza B and in school-aged children. What is New: • Here, we show over a 5-year period that viral myositis is strongly seasonal with up to 80% of cases attributable to influenza. • Influenza-associated myositis (IAM) typically occurs in boys, aged 5-9 years, with influenza B and is most often benign. Early clinical recognition may avoid unnecessary treatment and testing.

Entities:  

Keywords:  Epidemiology; Influenza; Myositis; Rhabdomyolysis

Mesh:

Year:  2020        PMID: 33095429     DOI: 10.1007/s00431-020-03835-w

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  3 in total

1.  Acute myositis associated with influenza B infection.

Authors:  D E Dietzman; J G Schaller; C G Ray; M E Reed
Journal:  Pediatrics       Date:  1976-02       Impact factor: 7.124

2.  Clinical features of influenza A and B in children and association with myositis.

Authors:  Jen-Jan Hu; Chuan-Liang Kao; Ping-Ing Lee; Chung-Ming Chen; Chin-Yun Lee; Chun-Yi Lu; Li-Min Huang
Journal:  J Microbiol Immunol Infect       Date:  2004-04       Impact factor: 4.399

3.  Fatal rhabdomyolysis following influenza infection in a girl with familial carnitine palmityl transferase deficiency.

Authors:  K J Kelly; J S Garland; T T Tang; A L Shug; M J Chusid
Journal:  Pediatrics       Date:  1989-08       Impact factor: 7.124

  3 in total
  4 in total

1.  Duvira Antarctic polysaccharide inhibited H1N1 influenza virus-induced apoptosis through ROS mediated ERK and STAT-3 signaling pathway.

Authors:  Jingyao Su; Danyang Chen; Ruilin Zheng; Xia Liu; Mingqi Zhao; Bing Zhu; Yinghua Li
Journal:  Mol Biol Rep       Date:  2022-04-12       Impact factor: 2.742

Review 2.  Neuromuscular Complications of SARS-CoV-2 and Other Viral Infections.

Authors:  Sarah Jacob; Ronak Kapadia; Tyler Soule; Honglin Luo; Kerri L Schellenberg; Renée N Douville; Gerald Pfeffer
Journal:  Front Neurol       Date:  2022-06-24       Impact factor: 4.086

3.  Evaluation of the prevalence and clinical and laboratory features of acute viral myositis in children with influenza referred to the emergency department of Ali Asghar Tehran Hospital in 2019 and 2020.

Authors:  Motahare A Delavar; Hamidreza K Ebrahimi; Nafise Borhani; Pegah Karimian; Fahimeh Ehsanipour; Shabahang Jafarnejad; Somayeh Esmaeilian
Journal:  J Family Med Prim Care       Date:  2022-06-30

4.  Patterns of Viral Arthropathy and Myalgia Following COVID-19: A Cross-Sectional National Survey.

Authors:  Christopher M Herndon; Van Nguyen
Journal:  J Pain Res       Date:  2022-09-29       Impact factor: 2.832

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.